Technology
Health
Biotechnology
Sierra Oncology
$1.389876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.38
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.01 (0.73%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell SRRA and other stocks, options, ETFs, and crypto commission-free!
About
Sierra Oncology, Inc. Common Stock, also called Sierra Oncology, is a clinical stage drug development company of therapeutics for the treatment of patients with cancer. Read More It engages in the business of researching, developing, and commercializing therapies for the treatment of patients with cancer. The company was founded on May 8, 2003 and is headquartered in Vancouver, Canada.
CEO
Employees
79
Headquarters
Vancouver, British Columbia
Founded
2003
Market Cap
102.32M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
440.87K
High Today
$1.40
Low Today
$1.35
Open Price
$1.39
Volume
152.88K
52 Week High
$3.70
52 Week Low
$1.05
Collections
Technology
Health
Biotechnology
Cancer Prevention
Medical
Therapy
2015 IPO
Canada
News
Yahoo FinanceMay 8
Sierra Oncology Reports First Quarter 2019 Results
Momelotinib regulatory pathway clarity anticipated in Q2 2019 - - SRA737 Phase 1/2 preliminary clinical data anticipated at the 2019 ASCO Annual Meeting - VANCOUVER , May 8, 2019 /CNW/ - Sierra Oncology, Inc. ("Sierra Oncology") (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with unmet needs in hematology and oncology, today reported its financial and operational results for the first quarter ended March 31, 2019 . "During the fi...
PR NewswireMay 6
Sierra Oncology to Attend Two Investor Conferences in May
VANCOUVER, May 6, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced that members of its senior management team will be attending the SunTrust Robinson Humphrey 5th Annual Life Sciences Conference in New York on May 8th, and the Oppenheimer Oncology Insight Summit in New York on May 16th. Sun Trust Robinson Humphrey 5th An...
Price Paid on Robinhood
32% Lower
Right Now
52 Week Low
$1.05
Average Price Paid
$2.03
52 Week High
$3.70
Earnings
-$0.22
-$0.20
-$0.18
-$0.16
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 8, Pre-Market